Oxford Immunotec Global PLC (NASDAQ:OXFD) Stock Rating Lowered by Zacks Investment Research

Oxford Immunotec Global PLC (NASDAQ:OXFD) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report released on Saturday, November 4th.

According to Zacks, “Oxford Immunotec Global PLC is a medical diagnostics company. It develops new tests for various diseases based on its, patented T cell measurement technology. The company’s first product is the T-SPOT(R). Oxford Immunotec Global PLC is headquartered in Abingdon, the United Kingdom. “

Several other brokerages have also recently issued reports on OXFD. Cowen and Company restated a “buy” rating and set a $22.00 price objective on shares of Oxford Immunotec Global PLC in a research note on Thursday, August 3rd. BTIG Research started coverage on Oxford Immunotec Global PLC in a research note on Thursday, September 28th. They set a “buy” rating and a $21.00 price objective on the stock. ValuEngine cut Oxford Immunotec Global PLC from a “hold” rating to a “sell” rating in a research note on Tuesday, October 31st. Robert W. Baird restated a “buy” rating and set a $20.00 price objective on shares of Oxford Immunotec Global PLC in a research note on Wednesday, November 1st. Finally, Piper Jaffray Companies restated a “buy” rating and set a $26.00 price objective on shares of Oxford Immunotec Global PLC in a research note on Thursday, August 3rd. Two investment analysts have rated the stock with a sell rating and four have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $19.75.

Oxford Immunotec Global PLC (NASDAQ OXFD) traded up $0.24 during trading hours on Friday, hitting $14.25. The company had a trading volume of 146,300 shares, compared to its average volume of 107,356. The company has a debt-to-equity ratio of 0.38, a quick ratio of 4.30 and a current ratio of 4.72. Oxford Immunotec Global PLC has a fifty-two week low of $12.19 and a fifty-two week high of $19.51.

TRADEMARK VIOLATION NOTICE: “Oxford Immunotec Global PLC (NASDAQ:OXFD) Stock Rating Lowered by Zacks Investment Research” was posted by BBNS and is the property of of BBNS. If you are reading this piece on another site, it was illegally stolen and reposted in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://baseballnewssource.com/markets/oxford-immunotec-global-plc-oxfd-downgraded-by-zacks-investment-research-to-sell/1758631.html.

In related news, CEO Peter Wrighton-Smith sold 55,000 shares of the stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $16.78, for a total value of $922,900.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Richard A. Sandberg sold 3,000 shares of the stock in a transaction that occurred on Friday, September 1st. The stock was sold at an average price of $15.82, for a total value of $47,460.00. Following the completion of the transaction, the director now directly owns 18,000 shares of the company’s stock, valued at $284,760. The disclosure for this sale can be found here. Insiders have sold 61,000 shares of company stock valued at $1,010,410 over the last ninety days. Corporate insiders own 8.11% of the company’s stock.

Hedge funds and other institutional investors have recently modified their holdings of the business. Parkwood LLC boosted its stake in Oxford Immunotec Global PLC by 12.9% during the 2nd quarter. Parkwood LLC now owns 12,799 shares of the company’s stock valued at $215,000 after purchasing an additional 1,465 shares in the last quarter. Voya Investment Management LLC boosted its stake in Oxford Immunotec Global PLC by 16.0% during the 2nd quarter. Voya Investment Management LLC now owns 13,345 shares of the company’s stock valued at $224,000 after purchasing an additional 1,845 shares in the last quarter. American International Group Inc. boosted its stake in Oxford Immunotec Global PLC by 7.1% during the 1st quarter. American International Group Inc. now owns 13,668 shares of the company’s stock valued at $212,000 after purchasing an additional 904 shares in the last quarter. Nationwide Fund Advisors boosted its stake in Oxford Immunotec Global PLC by 1.9% during the 1st quarter. Nationwide Fund Advisors now owns 13,765 shares of the company’s stock valued at $213,000 after purchasing an additional 254 shares in the last quarter. Finally, Alliancebernstein L.P. bought a new position in Oxford Immunotec Global PLC during the 2nd quarter valued at $247,000. 80.57% of the stock is owned by hedge funds and other institutional investors.

Oxford Immunotec Global PLC Company Profile

Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology.

Get a free copy of the Zacks research report on Oxford Immunotec Global PLC (OXFD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Oxford Immunotec Global PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global PLC and related companies with our FREE daily email newsletter.

 


Latest News

Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Yankees and Marlins Continue Stanton Trade Talks
Yankees and Marlins Continue Stanton Trade Talks
Marlins Making Moves, Trade Dee Gordon to Seattle
Marlins Making Moves, Trade Dee Gordon to Seattle
Report: Astros Dallas Keuchel Pitched With Injured Foot
Report: Astros Dallas Keuchel Pitched With Injured Foot
Angels Sign Former Prospect with Braves Kevin Maitan
Angels Sign Former Prospect with Braves Kevin Maitan
Shohei Ohtani Has Turned Down Red Sox and Yankees
Shohei Ohtani Has Turned Down Red Sox and Yankees


Leave a Reply

 
© 2006-2017 BBNS.